ERBB2 and breast carcinoma: Among the key mechanisms contributing to drug resistance against CDK4/6iin HR‐positive/HER2‐negative breast cancer cells, upregulation of the PI3K/mTOR pathway is particularly common, making it a promising target for overcoming resistance [5, 36].